BOULDER, Colo. — Clovis Oncology Inc. (CLVS) on Wednesday reported a loss of $66.4 million in its second quarter.
On a per-share basis, the Boulder, Colorado-based company said it had a loss of 61 cents.
The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 57 cents per share.
The biopharmaceutical company posted revenue of $36.8 million in the period, also missing Street forecasts. Four analysts surveyed by Zacks expected $40.8 million.
The company’s shares closed at $4.86. A year ago, they were trading at $6.14.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLVS at https://www.zacks.com/ap/CLVS